Bradley Collins, DO
Rheumatology · Summerville, SCNPI 1326533308
Payments from drug & device makers
Across 298 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- Johnson & Johnson$1K
- UCB, Inc.$491
- Novartis$434
- Lilly USA, LLC$412
- plus $1K from 16 others
What the payments were for
- Food & beverage$6,027100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 61 | $1,286 |
| AbbVie | 53 | $1,045 |
| Johnson & Johnson | 52 | $1,024 |
| UCB, Inc. | 25 | $491 |
| Novartis | 21 | $434 |
| Lilly USA, LLC | 19 | $412 |
| Sandoz | 20 | $315 |
| AstraZeneca(2 entities) | 11 | $226 |
| Pfizer | 9 | $191 |
| Aurinia Pharma U.S., Inc. | 6 | $143 |
| Radius Health, Inc. | 4 | $98 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Fresenius Kabi USA, LLC | 2 | $50 |
| GSK | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Sanofi | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Organon | 1 | $21 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$6,027 in reported general payments places this provider in the 50th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 23 | $211,368 |
| Enbrel SureclickEtanercept | 11 | $123,603 |
| Orencia ClickjectAbatacept | 12 | $81,224 |
| Hydroxychloroquine Sulfate | 110 | $4,502 |
| MethotrexateMethotrexate Sodium | 93 | $2,766 |
| Leflunomide | 27 | $2,027 |
| Celecoxib | 23 | $1,245 |
| Mycophenolate Mofetil | 13 | $1,107 |
| Methylprednisolone | 59 | $1,071 |
| Prednisone | 131 | $750 |
| Allopurinol | 44 | $360 |
| Alendronate Sodium | 15 | $281 |
| Meloxicam | 30 | $169 |
| Folic Acid | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Summerville
- Clarence LegertonSummerville$7.7M
- Gary FinkSummerville$6.9M
- William EdwardsSummerville$5.9M
- Colin EdgertonSummerville$4.6M
- Gregory NiemerSummerville$4.4M
- Jennifer MurphySummerville$4.4M
- Nicholas HoldgateSummerville$533K
- Richard SilverCharleston$1.6M
- Alan BrownGreenville$947K
- Mitchell FeinmanOrangeburg$824K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.